In an effort to verify whether these novel models with different genetic aberrations exhibited a similar anti-tumor response to targeted therapy, we tested the efficacy of gefitinib in model L115, harboring an exon 19 deletion within EGFR. Gefitinib is an anti-EGFR agent shown to have clinical activity for the treatment of EGFR mutation positive NSCLC patients [32]. This evidence concerns the gene EGFR and neoplasm.